Engene Therapeutics Warrant 10/31/2028 has returned -39.9% from $3.33 since 2026, trailing SPY's +5.8% over the same period. The stock hit an all-time high of $3.33 in Mar 2026 and is currently 39.9% below that level. 4 news events tracked with market reaction data.
Expand to read Wikipedia-sourced background on the company. Click any linked term to explore it inline — no page reload.
Common questions answered from real data: performance vs SPY, market cap, profitability, CEO, dividends, and more.
Every dot on the chart is a news event. The return shown is market-adjusted (vs SPY). Green = stock outperformed. Red = underperformed. Dot size = magnitude of reaction.
Want the full written briefing?
The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.
| Date | Return | Category | Source | Headline |
|---|---|---|---|---|
| 2026-04-07 | -2.6% | news | Business Wire | enGene Announces Name Change to enGene Therapeutics Inc. |
| 2026-03-15 | -1.0% | legal | MarketBeat | enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference |
| 2026-03-15 | -1.0% | news | MarketBeat | enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference |
| 2026-03-15 | -1.0% | earnings | MarketBeat | enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update |